Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MIRM 
Mirum Pharmaceuticals Inc (MIRM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: MIRM (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
10 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $87.99
1 Year Target Price $87.99
| 6 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 54.24% | Avg. Invested days 47 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.75B USD | Price to earnings Ratio - | 1Y Target Price 87.99 |
Price to earnings Ratio - | 1Y Target Price 87.99 | ||
Volume (30-day avg) 10 | Beta 0.42 | 52 Weeks Range 36.88 - 78.54 | Updated Date 11/30/2025 |
52 Weeks Range 36.88 - 78.54 | Updated Date 11/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-11-04 | When - | Estimate -0.15 | Actual 0.05 |
Profitability
Profit Margin -8.78% | Operating Margin (TTM) 1.96% |
Management Effectiveness
Return on Assets (TTM) -3.6% | Return on Equity (TTM) -15.81% |
Valuation
Trailing PE - | Forward PE 833.33 | Enterprise Value 3697516580 | Price to Sales(TTM) 7.96 |
Enterprise Value 3697516580 | Price to Sales(TTM) 7.96 | ||
Enterprise Value to Revenue 7.84 | Enterprise Value to EBITDA -8.85 | Shares Outstanding 51393574 | Shares Floating 43874694 |
Shares Outstanding 51393574 | Shares Floating 43874694 | ||
Percent Insiders 1.88 | Percent Institutions 113.89 |
Upturn AI SWOT
Mirum Pharmaceuticals Inc
Company Overview
History and Background
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company founded in 2018. It focuses on developing and commercializing novel therapies for debilitating liver diseases.
Core Business Areas
- Hepatology: Mirum focuses on developing and commercializing therapies for rare liver diseases, particularly those affecting children.
Leadership and Structure
Chris Peetz serves as the President and CEO. The company has a typical structure with departments such as Research and Development, Commercial, Finance, and Operations.
Top Products and Market Share
Key Offerings
- LIVMARLI (maralixibat): LIVMARLI is approved for treating cholestatic pruritus in patients with Alagille syndrome (ALGS). Market share data can be obtained from Mirum's financial reports and analyst estimates. Competitors in this space include companies developing treatments for cholestatic liver diseases, though LIVMARLI has a strong position in ALGS-related pruritus.
Market Dynamics
Industry Overview
The industry focuses on developing treatments for liver diseases, particularly rare and pediatric conditions. This involves significant research and development, regulatory approvals, and commercialization efforts.
Positioning
Mirum is positioned as a leader in developing therapies for rare pediatric liver diseases, particularly in cholestatic conditions. Its competitive advantage lies in its focus on specific, underserved patient populations and its first-mover advantage with LIVMARLI.
Total Addressable Market (TAM)
The TAM for rare liver diseases is substantial and growing, driven by increasing awareness, improved diagnostics, and the development of targeted therapies. Mirum is positioned to capture a significant portion of this market, especially in its core indications.
Upturn SWOT Analysis
Strengths
- Approved product (LIVMARLI)
- Focus on rare pediatric liver diseases
- Strong intellectual property
- Experienced management team
Weaknesses
- Reliance on a limited number of products
- High R&D expenses
- Commercialization risks
- Dependence on regulatory approvals
Opportunities
- Expansion into new indications
- Geographic expansion
- Acquisition of new assets or technologies
- Partnerships and collaborations
Threats
- Competition from other pharmaceutical companies
- Regulatory hurdles
- Pricing and reimbursement pressures
- Clinical trial failures
Competitors and Market Share
Key Competitors
- MYOV
- ICPT
- AKCA
Competitive Landscape
Mirum's competitive advantage lies in its focus on rare pediatric liver diseases and its approved product. It faces competition from larger pharmaceutical companies and other biotechs in the liver disease space. Its specialized focus is a considerable advantage.
Major Acquisitions
Albireo Pharma
- Year: 2022
- Acquisition Price (USD millions): 540
- Strategic Rationale: To acquire new products and pipeline assets focused on liver diseases, expanding Mirum's portfolio.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by the commercial launch of LIVMARLI and pipeline development.
Future Projections: Future growth depends on the expansion of LIVMARLI's market, new product approvals, and strategic partnerships. Analyst estimates are needed for concrete projections.
Recent Initiatives: Recent initiatives include clinical trials for new indications, market expansion efforts, and collaborations.
Summary
Mirum Pharmaceuticals is a focused biopharmaceutical company with an approved product addressing a specific need in rare liver diseases. The company's growth depends on expanding the market for its current product and successfully developing its pipeline. Competition in the liver disease space and regulatory hurdles are key challenges. The company should focus on leveraging its position in its niche and continue to expand its pipeline through organic development or acquisitions. They need to be aware of companies that develop similar products.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Mirum Pharmaceuticals Inc. SEC Filings
- Company Website
- Analyst Reports (FactSet, Bloomberg)
- Industry Reports
Disclaimers:
This analysis is based on available information and general market knowledge. It should not be considered financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mirum Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Foster City, CA, United States | ||
IPO Launch date 2019-07-18 | CEO & Director Mr. Christopher Peetz | ||
Sector Healthcare | Industry Biotechnology | Full time employees 355 | Website https://www.mirumpharma.com |
Full time employees 355 | Website https://www.mirumpharma.com | ||
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.